🇺🇸 LOXO-305 in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fall — 1 report (14.29%)
  2. Haematochezia — 1 report (14.29%)
  3. Hypertension — 1 report (14.29%)
  4. Hypertensive Urgency — 1 report (14.29%)
  5. Infusion Related Reaction — 1 report (14.29%)
  6. Small Intestinal Obstruction — 1 report (14.29%)
  7. Subdural Haematoma — 1 report (14.29%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is LOXO-305 approved in United States?

LOXO-305 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for LOXO-305 in United States?

Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.